Tilray | TRLY - Operating Expenses

Stock Price
9.48
Daily Change
-0.03 -0.32%
Monthly
-7.60%
Yearly
977.27%
Q1 Forecast
9.24

Tilray reported $237.52M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acasti Pharma USD 62.82M 59.73M Sep/2025
Akebia Therapeutics USD 43.82M 16.98M Mar/2025
Alaunos Therapeutics USD 1.19M 428K Sep/2025
Aurora Cannabis CAD 146.03M 27.79M Sep/2025
Avita Medical AUD 28.02M 1.55M Dec/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Cronos Group USD 51.59M 70.5M Dec/2025
Dianthus Therapeutics USD 40.68M 5.56M Sep/2025
Divis Laboratories Ltd INR 18.32B 1.08B Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
IQVIA Holdings USD 1.69B 4.47B Dec/2025
Knight Therapeutics CAD 89.06M 2.02M Sep/2024
Moderna USD 1.54B 259M Dec/2025
Organigram Holdings CAD 108.11M 17.03M Sep/2025
Organon & Co USD 906M 362M Sep/2025
Revvity USD 626.22M 25.62M Dec/2025
Tectonic Therapeutic USD 21.89M 440K Sep/2025
Tilray USD 237.52M 17.34M Sep/2025
Viatris USD 3.86B 335.7M Dec/2025
Xeris Pharmaceuticals USD 67.65M 590K Sep/2025